Gilead to buy back another $5 billion of shares
(Reuters) - Gilead Sciences Inc (GILD.O), maker of new hepatitis C treatment Sovaldi, on Wednesday said its board has authorized the repurchase of up to $5 billion of the company's shares.
The latest authorization augments the approximate $2.9 billion remaining in Gilead's previous buy back program, which the company said is expected to be completed by September.
Gilead said the new program expires three years after the completion of the current repurchase program.
Immediately after the announcement, shares of Gilead jumped as much as 1.4 percent from their closing price of $78.77 on Nasdaq, then eased back to stand up 63 cents, or 0.8 percent, after hours.
(Reporting By Deena Beasley; Editing by David Gregorio)
NEW YORK - U.S. stocks inched higher on Thursday and the S&P reached a record high, lifted by data pointing to steady improvement in the economy, as investors awaited the start of a meeting of top central bankers and economists in Jackson Hole, Wyoming.
BEIJING/HONG KONG - China reiterated its opposition on Thursday to a European Union plan to limit airline carbon dioxide emissions and called for talks to resolve the issue a day after its major airlines refused to pay any carbon costs under the new law.